The table below shows Aldeyra Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$5.11M
-$12.47M
-$9.97M
-$9.44M
-$12.87M
-$13.47M
Capital expenditure
-
-
-
$0.00
$16.32K
$7.81K
Investing cash flow
$0.00
$7.29M
-$30.38M
$30.00M
-$58.03M
-$7.81K
Dividends paid
-
-
-
-
ALDX operating cash flow (10-K history)
Aldeyra Therapeutics, Inc. reported operating cash flow of -$33.35M for fiscal year 2025. That is up 22.8% from -$43.21M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$19.22M (FY 2017) to -$33.35M. Figures come from the company's audited annual reports as filed with the SEC.